BIIB - バイオジェン (Biogen Inc.) バイオジェン

 BIIBのチャート


 BIIBの企業情報

symbol BIIB
会社名 Biogen Inc (バイオジェン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 医薬品   医療関連(Health Care)
概要 事業概要 バイオジェン(Biogen Inc.)は生物技術会社である。同社は神経学的疾患、希少疾患、自己免疫疾患の治療製品の発見・開発・製造・提供に従事する。同社は多発性硬化症(MS)の治療用「ECFIDERA」、「AVONEX」、「PLEGRIDY」、「TYSABRI」、「ZINBRYTA」、「FAMPYRA」、重症プラーク乾癬の治療用「FUMADERM」、脊髄性筋萎縮症(SMA)の治療用「SPINRAZA」を含む製品を販売する。同社はまた非ホジキンリンパ腫、慢性リンパ球性白血病(CLL)等の治療用「RITUXAN」に関連するRoche GroupのメンバーであるGenentech、Inc.(Genentech)との共同契約を締結して、CLLと濾胞性リンパ腫の治療用「GAZYVA」、他の抗CD20療法を提供する。同社は製品候補はOCREVUS、バイオシミラー・アダリムマブ、Aducanumab、E2609、BIIB074、BAN2401、オピシヌマブ、CIARA、BIIB061、BIIB054、BIIB067、BIIB068を含む。   バイオジェンはバイオ医薬品企業。神経疾患治療の医薬品の開発・製造・販売に従事する。再発性多発性硬化症(MS)治療薬、クロ―ン病治療薬、非ホジキンリンパ腫と関節リウマチ治療薬などが主要製品。また、潰瘍性大腸炎などの自己免疫疾患のほか、血友病、リンパ性白血病、非ホジキンリンパ腫の治療薬も扱う。本社はマサチュ―セッツ州ケンブリッジ。   At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.
本社所在地 225 Binney Street Cambridge MA 02142 USA
代表者氏名 Stelios Papadopoulos Stelios Papadopoulos
代表者役職名 Independent Chairman of the Board
電話番号 +1 781-464-2000
設立年月日 31229
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 7300人
url www.biogen.com
nasdaq_url https://www.nasdaq.com/symbol/biib
adr_tso
EBITDA EBITDA(百万ドル) 6760.6
終値(lastsale) 343.03
時価総額(marketcap) 69100940835.5
時価総額 時価総額(百万ドル) 69411.16
売上高 売上高(百万ドル) 12872.4
企業価値(EV) 企業価値(EV)(百万ドル) 72115.36
当期純利益 当期純利益(百万ドル) 4141.8
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Biogen Inc revenues increased 10% to $6.49B. Net income increased 27% to $2.04B. Revenues reflect Product net increase of 5% to $5.28B Revenue Sales of Goods_Services increase of 27% to $933.6M Other Rev from Biz Related Activ. increase from $131.6M to $273M. Net income benefited from Amortization of acquired intangible asse decrease of 63% to $211.3M (expense).

 BIIBのテクニカル分析


 BIIBのニュース

   STAT+: Pharmalittle: Biogen yanks Alzheimers paper from JAMA over edits; Pfizer sees $33.5 billion in Covid-19 vax sales  2021/07/28 13:38:05 STAT News
Gayle Smith, head of global Covid-19 response at the State Department, urged U.S. vaccine makers to back low-cost manufacturing hubs overseas.
   The 9 behind-the-scenes professionals you need to know in digital health  2021/07/28 12:46:44 Business Insider
Summary List Placement Hello, Welcome to Insider Healthcare. I''m Lydia Ramsey Pflanzer, and today in healthcare news: We found 9 players working behind the scenes who can make or break a digital health startup ; It''s back to wearing masks indoors, even for those fully vaccinated, CDC says ; Here''s the presentation Deep Genomics used to raise $180 million from investors including SoftBank and Khosla . If you''re new to this newsletter, sign up here. Comments, tips? Email me at lramsey@insider.com or tweet @lydiaramsey125 . Let''s get to it As coronavirus cases continue to surge in the US fueled by the Delta variant, the CDC introduced new masking guidelines . Everyone should mask up indoors, whether vaccinated or not , in areas of the country at higher risk from the virus. The CDC also recommended that everyone in K-12 schools wear a mask indoors. CDC Director Rochelle Walensky said on Tuesday that new data about Delta had prompted the change from May, when the CDC had said that masks were no longer necessary for fully vaccinated people.
   Global Adalimumab Market Will Reach $ 28,508.07 Million by 2027||Players-CELLTRION INC., Samsung Bioepis (a subsidiary of Samsung Biologics), Biogen, Coherus BioSciences, Innovent Biologics, Inc., Mylan N.V., Zydus Cadila  2021/07/28 08:26:43 OpenPR
Adalimumab market report presents the best market and business solutions to Pharmaceutical industry in this rapidly revolutionizing market place to thrive in the market. Market definition gives the scope of particular product with respect to the driving factors and restraints
   Emerging Therapies such as TMS-007 (Biogen), Trans-Sodium Crocetinate (TSC) (Diffusion Pharmaceuticals), and others Expected to Positively Impact the Hypoxia Market Scenario in the Upcoming Years  2021/07/27 22:30:03 AB Newswire
   Biogen withdrew paper on Alzheimer''s drug Aduhelm from JAMA after requested edits - Axios  2021/07/27 18:05:38 Seeking Alpha
   Biogen's Retinal Disease Gene Therapy Flunks Mid-Stage Study  2021/05/14 12:30:18 Benzinga
Biogen Inc (NASDAQ: BIIB ) has announced topline results from the Phase 2/3 XIRIUS study evaluating cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP). XLRP is a rare, inherited retinal disease associated with progressive vision loss as the retina's light-sensing cells gradually deteriorate. The XIRIUS study did not meet … Full story available on Benzinga.com
   Biogen, Capsigen Ink $1.3B AAV Capsids Development Pact For CNS & Neuromuscular Disorders  2021/05/11 13:05:46 Benzinga
Biogen Inc (NASDAQ: BIIB ) and Capsigen Inc have entered into a strategic research collaboration to engineer novel adeno-associated virus (AAV) capsids with the potential to deliver gene therapies for various CNS and neuromuscular disorders. As … Full story available on Benzinga.com
   Denali-Biogen Parkinson's Disease Candidate Shows Reductions In Biomarkers; Late Study To Begin By 2021 End  2021/05/03 10:46:13 Benzinga
Denali Therapeutics Inc (NASDAQ: DNLI ) has announced final results from Phase 1 and Phase 1b studies evaluating BIIB122/DNL151 Parkinson's disease. The drug is being developed in collaboration with Biogen Inc (NASDAQ: BIIB ). The results will be presented at the International Association of Parkinsonism and Related Disorders Virtual Congress. Results from the Phase 1 study of healthy volunteers (N=184) and the Phase 1b study of patients with Parkinson's disease … Full story available on Benzinga.com
   Biogen's Shares Are Trading Lower On 71% Quarterly Profit Slump, Weak Tecfidera Sales  2021/04/22 14:50:22 Benzinga
Biogen Inc (NASDAQ: BIIB ) reported a 70.7% fall in Q1 profit as its top-selling multiple sclerosis drug Tecfidera faced increased competition from cheaper generic drugs. Net income fell to $410.2 million, or $2.69 per share for the quarter from $1.40 billion, or $8.08 per share, a year earlier. Adjusted EPS came in at $5.34, down from $9.14 a year ago, but higher than the … Full story available on Benzinga.com
   Biogen quarterly profit slumps about 71% on MS drug competition  2021/04/22 11:30:25 Investing.com
https://www.investing.com/news/stock-market-news/biogen-quarterly-profit-slumps-about-71-on-ms-drug-competition-2482097
   Global Oligonucleotide Therapy Market Report 2020-2030: COVID-19 Impacts, Growth and Changes - ResearchAndMarkets.com  2021/03/23 14:36:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Oligonucleotide Therapy Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. The global oligonucleotide therapy market is expected to decline from $0.9 billion in 2019 to $0.88 billion in 2020 at a compound annual growth rate (CAGR) of -2.1%. Major players in the oligonucleotide therapy market are Alnylam Pharmaceuticals Inc., Biogen Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Merck
   Don't Lose Sight of Biogen's Depression Drug Amid Focus on Alzheimer's Disease  2021/03/18 13:39:00 Barron's
Truist analyst Robyn Karnauskas argues that investors should be paying more attention to the depression drug that Biogen is developing in partnership with Sage Therapeutics.
   Multiple Sclerosis Therapeutic Market Trend, Technology Innovations and Growth Prediction to 2025 Explore By Major Players Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co., Inc., AbbVie, Inc.  2021/03/18 07:25:29 OpenPR
The multiple sclerosis therapeutic agents are intended to promote neurorepair and neuroprotection to prevent disease progression. The disease modifying therapeutics are currently under clinical development to specifically target the disease while avoiding frequent therapeutic administrations. A variety of corticosteroids, immunosuppressants
   Covid 19 Analysis on Multiple Sclerosis Therapeutics Market Insights With Major Players: NOVARTIS AG, TEVA PHARMACEUTICAL INDUSTRIES LTD., SANOFI S.A., BAYER AG, PFIZER, INC., BIOGEN IDEC, MERCK & CO., INC., AND ABBVIE, INC.  2021/03/17 10:50:50 OpenPR
Multiple Sclerosis Therapeutics Market report provides key enumeration on the Market status of the Multiple Sclerosis Therapeutics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. The research was conducted using
   Biogen's $200M expansion is another boost to NC's growing biopharma sector | WRAL TechWire  2021/03/04 13:23:38 WRAL TechWire
Editor's note: Robin Deacle is Vice President, Corporate Communications, at the North Carolina Biotech Center. RESEARCH TRIANGLE PARK - North Carolina's gene

 関連キーワード  (医薬品 米国株 バイオジェン BIIB Biogen Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)